Sterigenics US LLC, of Oak Brook, Ill., has announced it will not reopen its ethylene oxide (EtO) sterilization plant in Willowbrook, Ill., a development that could strain the capacity for sterilization of devices such as duodenoscopes. Illinois is not the only state that is taking action on EtO, however, a predicament that suggests the U.S. federal government may have to insert itself into the discussion in order to avoid a shortage of critical, life-saving devices.

The FDA has reissued a 2017 draft guidance for clinical decision support (CDS) applications as part of a reexamination of software regulations, and one difference between the 2017 draft and the latest iteration that is sure to cheer developers is that the agency now provides much more clarity as to the types of functions that will and will not fall under regulatory scrutiny going forward.

BOSTON – The 2019 Medtech Conference included the annual FDA town hall session, and Jeff Shuren, director of the agency's device center, said the pace of scientific change is outstripping the agency's ability to keep up. Shuren said the solution might be "regulatory Legos," an approach that might eliminate the need to go to Congress for new statutory authorities every time device makers carve open a new technological frontier.

The FDA's Center for Devices and Radiological Health has released yet another draft guidance dealing with medical device premarket programs with the release of a draft guidance for the accreditation scheme for conformity assessment. The draft frequently references independent standards for assessing device performance and safety, thus bringing regulatory harmonization one step closer to a practicable reality.

The U.S. FDA's emphasis on device safety is well known. Now, the agency has published a draft guidance that aims to provide expedited reviews for device and diagnostic applications that are "reasonably expected to significantly improve" safety, which, in conjunction with the breakthrough devices program, suggests that many other applications will be in the queue for increasingly longer periods of time.

HONG KONG – Dreamed Diabetes Ltd., of Petah Tikva, Israel, has received both FDA clearance and the CE mark for an insulin dosing decision support software based on artificial intelligence (AI).

Chronic bronchitis affects more than 9 million people in the U.S., but current treatments fail to address the overproduction of mucus. Gala Therapeutics Inc., of Menlo Park, Calif., is looking to change that.

The FDA granted breakthrough device status to Prescient Metabiomics' Lifekit Prevent colorectal neoplasia test. Prescient Metabiomics is a subsidiary of Carlsbad, Calif.-based Prescient Medicine Holdings Inc.